Bayer AG NA (BAYN) - Total Liabilities
Based on the latest financial reports, Bayer AG NA (BAYN) has total liabilities worth €84.54 Billion EUR (≈ $98.84 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Bayer AG NA long-term investment allocation to see how much of total assets are deployed in long-term investments.
Bayer AG NA - Total Liabilities Trend (1998–2025)
This chart illustrates how Bayer AG NA's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see BAYN total asset value.
Bayer AG NA Competitors by Total Liabilities
The table below lists competitors of Bayer AG NA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Twilio Inc
NYSE:TWLO
|
USA | $1.86 Billion |
|
Legrand SA
PA:LR
|
France | €11.95 Billion |
|
HCL Technologies Limited
NSE:HCLTECH
|
India | Rs382.68 Billion |
|
Fortescue Ltd
AU:FMG
|
Australia | AU$10.65 Billion |
|
Prudential Financial Inc
NYSE:PRU
|
USA | $738.16 Billion |
|
Axon Enterprise Inc.
NASDAQ:AXON
|
USA | $3.81 Billion |
|
OTP Bank Nyrt
BUD:OTP
|
Hungary | Ft41.14 Trillion |
|
Guotai Junan Securities Co Ltd
SHG:601211
|
China | CN¥1.68 Trillion |
Liability Composition Analysis (1998–2025)
This chart breaks down Bayer AG NA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Bayer AG NA's balance sheet to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.20 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.26 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.76 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bayer AG NA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bayer AG NA (1998–2025)
The table below shows the annual total liabilities of Bayer AG NA from 1998 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €84.54 Billion ≈ $98.84 Billion |
+7.28% |
| 2024-12-31 | €78.81 Billion ≈ $92.13 Billion |
-5.26% |
| 2023-12-31 | €83.18 Billion ≈ $97.25 Billion |
-3.22% |
| 2022-12-31 | €85.95 Billion ≈ $100.49 Billion |
-1.29% |
| 2021-12-31 | €87.07 Billion ≈ $101.80 Billion |
+0.84% |
| 2020-12-31 | €86.35 Billion ≈ $100.95 Billion |
+9.66% |
| 2019-12-31 | €78.74 Billion ≈ $92.06 Billion |
-1.74% |
| 2018-12-31 | €80.14 Billion ≈ $93.69 Billion |
+109.64% |
| 2017-12-31 | €38.23 Billion ≈ $44.69 Billion |
-24.07% |
| 2016-12-31 | €50.34 Billion ≈ $58.85 Billion |
+3.86% |
| 2015-12-31 | €48.47 Billion ≈ $56.67 Billion |
-3.09% |
| 2014-12-31 | €50.02 Billion ≈ $58.47 Billion |
+63.92% |
| 2013-12-31 | €30.51 Billion ≈ $35.67 Billion |
-6.88% |
| 2012-12-31 | €32.77 Billion ≈ $38.31 Billion |
-2.17% |
| 2011-12-31 | €33.49 Billion ≈ $39.16 Billion |
+2.71% |
| 2010-12-31 | €32.61 Billion ≈ $38.12 Billion |
+1.62% |
| 2009-12-31 | €32.09 Billion ≈ $37.52 Billion |
-11.28% |
| 2008-12-31 | €36.17 Billion ≈ $42.29 Billion |
+4.67% |
| 2007-12-31 | €34.56 Billion ≈ $40.40 Billion |
-19.71% |
| 2006-12-31 | €43.04 Billion ≈ $50.32 Billion |
+66.88% |
| 2005-12-31 | €25.79 Billion ≈ $30.15 Billion |
+1.51% |
| 2004-12-31 | €25.41 Billion ≈ $29.70 Billion |
+1.36% |
| 2003-12-31 | €25.07 Billion ≈ $29.30 Billion |
-4.55% |
| 2002-12-31 | €26.26 Billion ≈ $30.70 Billion |
+30.95% |
| 2001-12-31 | €20.05 Billion ≈ $23.45 Billion |
-0.38% |
| 2000-12-31 | €20.13 Billion ≈ $23.53 Billion |
+25.05% |
| 1999-12-31 | €16.10 Billion ≈ $18.82 Billion |
-3.02% |
| 1998-12-31 | €16.60 Billion ≈ $19.40 Billion |
-- |
About Bayer AG NA
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health care; speci… Read more